Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Last trade$40.56
Day change+$0.19 (+0.47%)
Day range$39.80 – $41.16
Volume1,650,494
Market cap$3.92B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$3.92B
Price / earnings
—
Price / book
2.38×
Price / sales
155.57×
EV / sales
171.25×
EV / EBITDA
-8.39×
Profitability
Earnings per share
-$4.70
Return on assets
-17.84%
Return on equity
-27.68%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.36×
Current ratio
16.21×
Quick ratio
16.21×
Cash ratio
1.36×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$376.72M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CRSP, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$12.67M
$10.18M
$1.46M
$864K
$889K
$892K
$865K
$35.69M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$12.67M
$10.18M
$1.46M
$864K
$889K
$892K
$865K
$35.69M
Selling, general and administrative
$17.87M
$17.55M
$17.18M
$18.4M
$16.93M
$18.92M
$19.3M
$18.12M
Research and development
$83.56M
$69.63M
$68.57M
$83.53M
$58.9M
$166.15M
$72.48M
$71.74M
Total operating expenses
$142.71M
$127.45M
$131.71M
$155.63M
$132.95M
$230.22M
$149.29M
$100.28M
Operating income
-$130.05M
-$117.27M
-$130.25M
-$154.76M
-$132.06M
-$229.32M
-$148.42M
-$64.59M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$111.36M
-$90.19M
-$122.09M
-$130M
-$105.82M
-$207.26M
-$134.89M
-$36.61M
Income taxes
$74K
$960K
$839K
$614K
$619K
$1.29M
$1.11M
$700K
Net income
-$111.44M
-$91.15M
-$122.93M
-$130.61M
-$106.44M
-$208.55M
-$136M
-$37.31M
Net income attributable to common shareholders
-$111.44M
-$91.15M
-$122.93M
-$130.61M
-$106.44M
-$208.55M
-$136M
-$37.31M
EBITDA
-$125.81M
-$112.99M
-$125.93M
-$149.1M
-$127.63M
-$224.68M
-$143.69M
-$59.75M
Basic earnings per share
-$1.15
-$0.94
-$1.28
-$1.37
-$1.17
-$2.40
-$1.58
-$0.44
Diluted earnings per share
-$1.15
-$0.94
-$1.28
-$1.37
-$1.17
-$2.40
-$1.58
-$0.44
Recent news
Company coverage with links to the original publishers.
CRISPR Therapeutics (CRSP) has been among the most searched stocks on Zacks.com. The stock has declined 19.3% over the past month, underperforming the S&P 500's -3% decline. While the company shows strong revenue growth projections (+873.2% for current fiscal year and +237.7% for next year), it carries a Zacks Rank #3 (Hold) rating and is trading at a premium valuation (F grade) relative to peers. The company is expected to remain unprofitable in the near term.
The article compares Amgen and Vertex Pharmaceuticals as investment options for 2027. Amgen offers diversified revenue streams across multiple drug franchises with lower valuation metrics but faces biosimilar competition and pricing pressures. Vertex demonstrates faster growth driven by cystic fibrosis dominance and promising pipeline candidates like Povetacicept, though at a premium valuation. The analyst recommends Vertex for long-term growth investors despite higher valuations, citing its superior growth trajectory and innovative pipeline.
CRISPR Therapeutics reported encouraging Phase 1 clinical data for zugo-cel, its allogeneic CAR-T cell therapy, across multiple autoimmune disease indications. In systemic sclerosis, 83% of patients achieved clinical response at Month 3 with maintained responses through Month 6+. All nine idiopathic inflammatory myopathy patients showed moderate to major improvement. The therapy demonstrated a favorable safety profile with no serious adverse events reported across 21 dosed patients. Dose escalation studies are ongoing with higher CAR-T cell expansion observed at increased dose levels.
The article compares Bristol Myers Squibb (BMY) and Vertex Pharmaceuticals (VRTX) as investment options for 2027. BMY trades at a cheaper valuation (9.8x forward P/E) with a 4.06% dividend yield but faces revenue concentration risks and uncertain recovery timeline. VRTX commands a higher valuation (29.8x forward P/E) but demonstrates superior growth prospects, strong margins (85.61%), and successful product launches like Alyftrek. The author recommends Vertex as the better choice, citing its strong execution and growth momentum despite higher valuation multiples.
CRISPR Therapeutics (CRSP) is receiving increased investor attention. The stock has underperformed the S&P 500 over the past month (-3.7% vs -5.4%). While the company shows strong revenue growth projections (+771.8% for current fiscal year), it carries a Zacks Rank #3 (Hold) rating and trades at a premium valuation (F grade). The company is expected to turn profitable next fiscal year with projected EPS of $3.73.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.